Dialogues in Cardiovascular Medicine - Vol 9 . No. 4 . 2004



Heart Failure




The evolving rationale of heart failure therapy
L. Tavazzi, E. Arbustini




Cardiac resynchronization therapy in heart failure: which type and for whom?
A. Auricchio, C. Fantoni


Multiple neurohormonal modulation: what are the most effective combinations?
M. Komajda


Why are we unable to completely control the activation of neurohormonal systems in chronic heart failure—and should we?
H. Drexler, K. C. Wollert




Trails of Discovery: Class III antiarrhythmic agents: serendipity or drug design?
J. D. Fitzgerald




M. Faircloth, J. Clark, M. Marber


Familial dilated cardiomyopathy: from clinical presentation to molecular genetics
A. Arbustini and others

Randomized trial of an education and support intervention to prevent readmission of patients with heart failure
H. M. Krumholz and others

Long-term trends in the incidence of and survival with heart failure
D. Levy and others

Differential gene expression and genomic patient stratification following left ventricular assist device support
B. C. Blaxall and others

Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure
A. Nohria and others
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study
P. Jong and others

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
D. L. Mann and others

Regenerative capacity of the myocardium: implications for treatment of heart failure
R. von Harsdorf and others

Do we understand who benefits from resynchronisation therapy?
O. A. Breithardt and others

Hypertrophic cardiomyopathy
P. Elliott and W. J. McKenna




© 2008 LES LABORATOIRES SERVIER, an incorporated company of SERVIER All Rights Reserved - Updates